ZNTL Description — Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor.
|
|
Free ZNTL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.60 out of 4) 62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|